Nerea Otegui
A5076969532- PI3K/AKT/mTOR signaling in cancer
- Mast cells and histamine
- Cancer Immunotherapy and Biomarkers
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- DNA Repair Mechanisms
- Lung Cancer Research Studies
- Lung Cancer Treatments and Mutations
- Synthesis and Biological Evaluation
- Inflammatory Bowel Disease
- Cancer Mechanisms and Therapy
- Diagnosis and treatment of tuberculosis
- Peptidase Inhibition and Analysis
- Glycosylation and Glycoproteins Research
- Microscopic Colitis
- Microbial Natural Products and Biosynthesis
- Immunotherapy and Immune Responses
- Medical Imaging and Pathology Studies
- Tannin, Tannase and Anticancer Activities
- Ferrocene Chemistry and Applications
- PARP inhibition in cancer therapy
- MicroRNA in disease regulation
Universidad de Navarra
2022-2024
Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública
2019
Universidad Autónoma de Madrid
2019
Immunotherapy resistance in non-small cell lung cancer (NSCLC) may be mediated by an immunosuppressive microenvironment, which can shaped the mutational landscape of tumor. Here, we observed genetic alterations PTEN/PI3K/AKT/mTOR pathway and/or loss PTEN expression >25% patients with NSCLC, higher frequency squamous carcinomas (LUSC). Patients PTEN-low tumors had levels PD-L1 and PD-L2 showed worse progression-free survival when treated immunotherapy. Development a Pten-null LUSC mouse model...
Eliciting DNA damage in tumor cells continues to be one of the most successful strategies against cancer. This is case for classical chemotherapy drugs and radiotherapy. In modern era personalized medicine, this strategy tries identify specific vulnerabilities identified each patient’s tumor, inflict certain cell contexts that end up massive cancer death. Cells rely on multiple repair pathways fix damage, but frequently exhibit defects these pathways, many times being tolerant damage. Key...
Abstract PTEN is mutated in ~10% lung squamous cell carcinoma (LUSC) patients, which results hyperactivation of PI3K-AKT-mTOR signaling pathways. Mutations the pathway influence configuration tumor microenvironment (TME). We have recently reported that mutations LUSC are associated with increased infiltration T regulatory immunosuppressive cells (Tregs) and fibrogenesis (PMID: 37311042). Moreover, we demonstrated induces resistance to anti-PD-1 therapy. Based on these findings, investigated...
<p>Supplementary Figure 2</p>
<p>Supplementary Figure 1</p>
<p>Supplementary Figure Legends</p>
<p>Supplementary Materials and Methods</p>
<p>Supplementary Figure 5</p>
<p>Supplementary Figure 4</p>
<p>Supplementary Figure 3</p>
<div>Abstract<p>Immunotherapy resistance in non-small cell lung cancer (NSCLC) may be mediated by an immunosuppressive microenvironment, which can shaped the mutational landscape of tumor. Here, we observed genetic alterations PTEN/PI3K/AKT/mTOR pathway and/or loss PTEN expression >25% NSCLC patients, with higher frequency squamous carcinomas (LUSCs). Patients PTEN-low tumors had levels PD-L1 and PD-L2 showed worse progression-free survival when treated immunotherapy....
<p>Supplementary Materials and Methods</p>
<p>Supplementary Figure Legends</p>
<p>Supplementary Figure 5</p>
<p>Supplementary Figure 4</p>
<p>Supplementary Figure 3</p>
<p>Supplementary Figure 2</p>
<p>Supplementary Figure 1</p>
<p>Supplementary Figure 4</p>